Artificial Intelligence (AI) in drug development involves using machine learning and computational models to improve the efficiency of drug discovery and development. AI can be used in a vareity of R&D applications, including to help identify potential drug targets, predict efficacy, optimize clinical trials, and accelerate the time-to-market for new drugs. Its use can result in reduced costs, errors, and time spent, ultimately speeding up delivery of therapeutics while supporting personalized treatments based on specific genetic profiles.
Over several years, we have been envisioning a future where advanced AI models and extensive data access power limitless in silico simulations of complex biology, enhancing in vitro and in vivo experiments and unlocking groundbreaking insights. In line with our vision, we integrate novel technology into our drug development to boost R&D. The objective is not only to shorten the time necessary to deliver innovative treatments to patients but also improve efficiency and reduce costs.
What is AI applied to Drug Development?
AI to accelerate and sharpen the R&D pathway
“Collaborating with AI startups can be transformative: Debiopharm enjoys a privileged access to the most innovative start-ups in this space thanks to the strategic investments led by our Innovation Fund, which inspire future-proof innovation.”
Because precision medicine must start with precision R&D strategies, we built strong convictions in the power of AI-driven biomarkers to help predict success in the early stages of clinical development.
How we're applying our expertise
Discovery of novel biomarkers
AI identifies patients that are most likely to benefit from a particular drug, increasing the success of a clinical trial
Optimized Trial design
Using digital twins, AI models can simulate clinical trials to predict outcomes, allowing pre-trial adjustments and saving resources and time
Accelerated patient recruitment
AI can accelerate the patient selection for clinical trials by using advanced analytics to identify suitable candidates based on genetics and disease
Collaboration with our portfolio startups
Genialis and DebiopharmSet Up Biomarker Discovery Collaboration Nucleai and Debiopharm
Launch Research Collaboration Investments' Portfolio
Insights from our Experts
Global pharmaceutical AI facts and figures
7.2B
$2.8B
$2.2B
25%
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577280/
Get Involved
Looking for tailored support for your digital health startup?
As Debiopharm’s strategic corporate fund, we not only invest but also provide strategic guidance to startups transforming Pharma R&D and cancer care.
Learn more
Join our digital revolution
Developing innovative therapies for patients is in our DNA. Is it in yours too?
Seize The Opportunity